Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05613088 · ClinicalTrials.gov registry record · Phase 2
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT05613088 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 106 participants.
The verdict
NCT05613088, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Interventions
- DRUG Paclitaxel
- DRUG Topotecan
- DRUG Pegylated Liposomal Doxorubicin (PLD)
- DRUG MORAb-202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2025-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05613088
The ClinicalTrials.gov registry entry for NCT05613088 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Paclitaxel is the first listed.
NCT05613088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05613088 about?
NCT05613088 is a clinical study titled "A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
What is the current status of trial NCT05613088?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2023-02-01. Estimated completion is 2025-09-10.
What interventions are being tested in trial NCT05613088?
The interventions under investigation include: Paclitaxel (DRUG), Topotecan (DRUG), Pegylated Liposomal Doxorubicin (PLD) (DRUG), MORAb-202 (DRUG).
Who is sponsoring clinical trial NCT05613088?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.